Aroa appoints experienced executive to board as long serving director retires

• Seasoned global healthcare executive Paul Shearer to join Aroa Biosurgery as a non-executive director
• Shearer spent more than 30 years at Fisher & Paykel Healthcare, playing a key role in its US expansion
• The appointment comes as long-serving US-based director John Pinion retires from the board

Special Report: Soft tissue repair company Aroa Biosurgery has made a board change with the appointment of Paul Shearer as a non-executive director to replace long-serving director John Pinion on his retirement. 

Shearer is a seasoned global healthcare executive with extensive experience in the medical device sector.

He spent more than 30 years at Fisher & Paykel Healthcare, including 20 years as senior vice president, sales & marketing, overseeing commercial operations across more than 50 markets and playing a key role in expanding the company’s US presence.

Shearer also held senior technology sector roles with Computercorp and ICL and currently serves as a director of Skellerup Holdings.

In welcoming Shearer to the team, Aroa founder and CEO Brian Ward said his experience would be invaluable as the New Zealand-based company looked to grow internationally.

“Paul’s experience leading the international sales growth of a New Zealand-headquartered medical device company, including a strong track record in the United States, will provide valuable insight as AROA continues to scale,” Ward said.

Long-serving board member to retire

Meanwhile, US-based medtech executive John Pinion – who has been on the Aroa Biosurgery (ASX:ARX) board as a non-executive director since 2015 – will retire.

Board chair Jim McLean thanked Pinion for his decade-long contribution, noting his guidance through numerous company milestones.

“John’s experience and insight have helped guide the company through a number of important milestones,” McLean said.

He also welcomed Shearer to the Aroa board.

“He brings deep global commercial experience that will strengthen the Board’s oversight as Aroa continues to execute its growth strategy,” he said.

The board changes come as Aroa continues to pursue growth opportunities in the global medical device market, reinforcing its focus on expanding commercial operations and strategic leadership.

The changes take place from today October 31 with Shearer to stand for election at Aroa’s next AGM.

This article was developed in collaboration with Aroa Biosurgery, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.